skip to Global Navigation Bar skip to main content


homeHome > About Us > Press Release > News

News

News Content
Daewoong Pharmaceutical signs export contract to New Zealand and Israel with Nabota
Date 2018-12-20 Hit 2169
list
News List
Prev Daewoong Pharmaceutical enters into new drug candidate ‘BBT-401’ joint development and technology transfer contract with Bridgebio
Next Daewoong Pharmaceutical’s ‘NABOTA’ becomes the first Korea-made Botulinum Toxin to obtain US FDA approval